{"organizations": [], "uuid": "1d7868a4df0bd33d58bb2bb49342677a3e0f925a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180110.html", "section_title": "Archive News &amp; Video for Wednesday, 10 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aimmune-extends-supply-agreement-w/brief-aimmune-extends-supply-agreement-with-golden-peanut-and-tree-nuts-for-experimental-allergy-treatment-idUSASB0C0IJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-10T21:03:00.000+02:00", "replies_count": 0, "uuid": "1d7868a4df0bd33d58bb2bb49342677a3e0f925a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aimmune-extends-supply-agreement-w/brief-aimmune-extends-supply-agreement-with-golden-peanut-and-tree-nuts-for-experimental-allergy-treatment-idUSASB0C0IJ", "ord_in_thread": 0, "title": "BRIEF-Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "aimmune therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 10 (Reuters) - Aimmune Therapeutics Inc:\n* AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY\n* AIMMUNE THERAPEUTICS INC - ‍NEWLY EXPANDED GLOBAL AGREEMENT SECURES EXCLUSIVE SUPPLY RELATIONSHIP THROUGH 2033​\n* AIMMUNE THERAPEUTICS INC - AR101 IS CURRENTLY IN PHASE 3 CLINICAL TRIALS, WITH PIVOTAL TOPLINE DATA EXPECTED IN FEBRUARY\n* AIMMUNE THERAPEUTICS INC - ‍AS PART OF AGREEMENT, AIMMUNE HAS GRANTED ADM A 300,000-SHARE EQUITY STAKE IN AIMMUNE​\n* AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY\n* AIMMUNE THERAPEUTICS - ‍ AGREEMENT GIVES CO EXCLUSIVE ACCESS TO ADDITIONAL GOLDEN PRODUCTS THAT COULD BE DEVELOPED INTO PEANUT ORAL IMMUNOTHERAPIES​ ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-10T21:03:00.000+02:00", "crawled": "2018-01-11T12:41:45.028+02:00", "highlightTitle": ""}